Wavefront guided transPRK in combination with accelerated CXL reduces irregular astigmatism and results in significant gains of CDVA in patients with stage II-III keratoconus. Longer-term follow-up and comparison of results with historical control eyes treated with the same accelerated CXL protocol and no TransPRK will further quantify these visual gains and help to identify any negative effect of combined treatment on corneal shape stability.